Friday, November 22, 2024

Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery

Related stories

Deep Instinct Expands Zero-Day Security to Amazon S3

Deep Instinct, the zero-day data security company built on...

Foxit Unveils AI Assistant in Admin Console

Foxit, a leading provider of innovative PDF and eSignature...

Instabase Names Junie Dinda CMO

Instabase, a leading applied artificial intelligence (AI) solution for...

Veradigm Unveils Ambient Scribe to Ease Healthcare Admin Burden

Veradigm, a leading provider of healthcare data and technology...
spot_imgspot_img

Collaboration combines expertise in computational chemistry, artificial intelligence and machine learning, to help advance discovery and development of medicines for difficult-to-drug targets

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision medicines, announced it has entered into a strategic research collaboration with Janssen Pharmaceutical NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets. The companies will combine their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets. The agreement was facilitated by Johnson & Johnson Innovation.

Since its founding in 2021, Odyssey has assembled a team of expert drug hunters with deep experience in immunology, oncology, medicinal chemistry and structural biophysics, and armed them with next-generation computational tools to solve difficult therapeutic challenges. This integration of in silico methods, cutting-edge experimental capabilities, and wet lab infrastructure enables the scientists at Odyssey to rapidly discover and develop potentially transformative medicines for patients.

Also Read: Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

“We are excited about this collaboration to push the boundaries of the drug discovery and development process, using the latest advancements in AI and ML to find solutions for serious diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “This collaboration between our chemists, biologists, and data scientists will help accelerate our joint drug discovery efforts through optimization of our tools, data sharing, and model development to discover and develop transformational medicines for patients in need.”

Under the terms of the agreement, Odyssey will work with discovery and therapeutic area experts and data scientists at Johnson & Johnson to deploy AI and ML to discover and optimize small molecule therapeutics against multiple targets. Odyssey will receive an upfront payment and is eligible for milestone payments and royalties.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img